Avacta Group plc, a life sciences company focused on developing targeted oncology drugs and diagnostics, will be announcing its unaudited interim results for the six months ended 30 June 2023 on Thursday 28 September 2023. The CEO, Alistair Smith, and CFO, Tony Gardiner, will provide a live presentation via Investor Meet Company on the same day at 11:00am BST. The presentation is open to all existing and potential shareholders, and questions can be submitted beforehand. The results presentation will also be posted on the company's website.
Avacta's Therapeutics Division is working on developing a pipeline of novel Affimer immunotherapies and pre|CISION tumour targeted chemotherapies. The aim is to address the lack of durable response to current cancer immunotherapies and reduce the severe systemic toxicities caused by chemotherapies. The company has five programs in the pipeline, as well as research collaborations and licensing partnerships. The lead program, AVA6000, is a pre|CISION tumour-targeted form of the chemotherapy doxorubicin, which is currently in Phase I clinical trials.
The Affimer platform is an alternative to antibodies and is designed to overcome the drawbacks of antibodies that currently dominate the immuno-diagnostics and immuno-therapeutics markets. The pre|CISION tumour targeting platform modifies chemotherapy to selectively release the active drug in tumour tissue, reducing systemic exposure and minimizing damage to healthy tissues. This platform aims to improve the safety and therapeutic potential of anti-cancer treatments.